Table 1.
Quality assessment and characteristics of the included studies.
| Authors (Year) | Study Design (LOE) |
MQOE | Intervention | Comparator(s) | Mean Age, Years | Follow Up (FU), Months | MF, n | MF + PRP, n | others, n | OLT size | Outcomes Recorded | Administration Modalities |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Doğar et al. [28] (2021) |
RCT (2) |
83 (good) |
Arthroscopic MF with PRP | Arthroscopic MF only/arthroscopic MF with BST-CarGel | MF: 33 ± 13.2 MF + PRP: 45.6 ± 11.8 MF + BST: 35.6 ± 12 |
Mean FU: MF: 24 ±15 MF + PRP: 30 ± 24 MF + BST: 25 ± 12.2 Range: - |
22 | 19 | 22 | Control: 1.2 cm2 MF: 1.14 cm2 MF + BST-CarGel: 1.5 cm2 |
AOFAS, FAAM, VAS, time to postoperative return to sport activity | Single injection of PRP (SmartPReP2 system) 24 h after the operation/BST-CarGel mixed with blood through arthroscopic cannula intraoperatively |
| Görmeli et al. [29] (2015) |
RCT (1) |
86 (excellent) |
Arthroscopic MF with PRP | Arthroscopic MF with HA/arthroscopic MF with saline | MF + Saline: 40.3 ± 9.4 MF + HA: 39.7 ± 8.7 MF + PRP: 38.6 ± 9.1 |
15.3 Range: 11–25 |
13 | 13 | 14 | PRP: 1.3 cm2 (0.5–1.4) Control: 1.2 cm2 |
AOFAS, VAS | Single injection of PRP (SmartPReP2 system) 6 and 24 h after the operation |
| Guney et al. [6] (2013) |
RCT (2) |
73 (good) |
Arthroscopic MF with PRP | Arthroscopic MF only | MF: 42.8 ± 14.7 MF + PRP: 38.6 = 5 ± 12.7 |
Mean FU 16.2 Range 12–84 |
16 | 19 | - | - | AOFAS, FAAM, VAS | Single injection of PRP (SmartPReP2 system [Harvest Autologous Hemobiologics]) 6 and 24 h after the operation |
| Guney et al. [30] (2015) |
Quasi-RCT (2) |
75 (good) |
Arthroscopic MF with PRP | Arthroscopic MF only/mosaicplasy | MF: 33 ± 13.2 MF + PRP: 45.6 ± 11.8 Mosaicplasty: 35.6 ± 12 |
Mean FU: MF: 47.3 ± 16.9 MF + PRP: 40.4 ± 10.4 Mosaicplasty: 30.1 ± 13.1 Range: 12–24 |
19 | 22 | 13 | PRP: <20 mm Control: <20 mm |
AOFAS, FAAM, VAS | Single injection of PRP (SmartPReP2 system) 6 and 24 h after the operation |
| Yang et al. [31] (2020) |
RCT (2) |
78 (good) |
Arthroscopic MF with PRP | Arthroscopic MF only | MF: 36.5 MF + PRP: 35.9 |
Mean FU: 15.6 Range: 12–18 |
21 | 22 | - | 0.93 ± 0.41 cm | AOFAS, VAS | Single injection of PRP (3 mL autologous PRP plus 10% CaCl2 0.3 mL), 4 weekly injections after the operation |
Abbreviations: RCT: randomized controlled trial; LOE: level of evidence; MQOE: methodologic quality of evidence; h: hour. Data are presented as means ± standard deviation. Dashes indicate information not reported.